Key features and details
- One-wash 90 minute protocol
- Sensitivity: 2.5 ng/ml
- Range: 17.2 ng/ml - 1100 ng/ml
- Sample type: Cerebral Spinal Fluid, Cit plasma, EDTA Plasma, Hep Plasma, Serum, Urine
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman Lipoprotein A ELISA Kit
See all Lipoprotein a kits
Intra-assay Sample n Mean SD CV% Serum 5 1.8% Inter-assay Sample n Mean SD CV% Serum 3 2%
Sample typeUrine, Serum, Hep Plasma, EDTA Plasma, Cit plasma, Cerebral Spinal Fluid
Assay typeSandwich (quantitative)
Range17.2 ng/ml - 1100 ng/ml
Sample specific recovery Sample type Average % Range Cell culture supernatant 102 99% - 105% Urine 107 107% - 108% Serum 99 97% - 103% Hep Plasma 104 100% - 107% EDTA Plasma 104 101% - 108% Cit plasma 102 99% - 105% Cerebral Spinal Fluid 109 108% - 110%
Assay time1h 30m
Assay durationOne step assay
Species reactivityReacts with: Human
Does not react with: Cow
Human Lipoprotein A ELISA Kit (ab212165) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Lipoprotein A protein in cerebral spinal fluid, serum, urine, cit plasma, edta plasma, and hep plasma. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Lipoprotein A with 2.5 ng/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Lipoprotein A is an atherogenic lipoprotein particle formed by an assembly of LDL particles and apo(a) bound to apoB-100 component of LDL. Apolipoprotein A, the main constituent of Lipoprotein A, has serine proteinase activity and is capable of autoproteolysis. Apolipoprotein A has 4,548 amino acids, variable sizes from 200 to 700 kDa, multiple isoforms, and structural homology with plasminogen. It competes with plasminogen for its binding site, inhibiting tissue-type plasminogen activator 1 and leading to reduced fibrinolysis. High levels of Lipoprotein A in the blood is a risk factor for myocardial infarction (MI), coronary heart disease (CHD), cerebrovascular disease (CVD), atherosclerosis, thrombosis, and stroke.
PlatformPre-coated microplate (12 x 8 well strips)
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 10X Human Lipoprotein A Capture Antibody 1 x 600µl 10X Human Lipoprotein A Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent CPI - HAMA Blocker (ab193969) 1 x 6ml Human Lipoprotein A Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
RelevanceLipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.
- Antiangiogenic AK38 protein
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
Background-subtracted data values (mean +/- SD) are graphed.
The concentrations of Lipoprotein A were measured in duplicate, interpolated from the Lipoprotein A standard curve, and corrected for sample dilution. Undiluted samples are as follows: serum 0.25%, plasma (citrate) 0.25%, plasma (heparin) 0.25% and plasma (EDTA) 0.125%. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 309 μg/mL in serum, 291 μg/mL in plasma (citrate), 520 μg/mL in plasma (EDTA), and 150 μg/mL in plasma (Heparin).
The concentrations of Lipoprotein A were measured in duplicates, interpolated from the Lipoprotein A standard curves and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 500 ng/mL in urine, and 130 ng/mL in cerebrospinal fluid.
Interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Lipoprotein A concentration was determined to be 169 µg/mL with a range of 42 – 576 µg/mL.
To learn more about the advantages of recombinant antibodies see here.
ab212165 has not yet been referenced specifically in any publications.